Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer

Drug Design, Development and Therapy
Kaizhou JinXianjun Yu

Abstract

Pancreatic ductal adenocarcinoma (PDAC), a common digestive system cancer, is highly malignant and has a poor disease outcome. Currently, all available examination and detection methods cannot accurately predict the clinical outcome. Therefore, it is extremely important to identify novel molecular biomarkers for personalized medication and to significantly improve the overall outcome. The "noncoding RNAs" (ncRNAs) are a group of RNAs that do not code for proteins, and they are categorized as structural RNAs and regulatory RNAs. It has been shown that microRNAs and long ncRNAs function as regulatory RNAs to affect the progression of various diseases. Many studies have confirmed a role for ncRNAs in the progression of PDAC during the last few years. Because of the significant role of ncRNAs in PDAC, ncRNA profiling may be used to predict PDAC outcome with high accuracy. This review comprehensively analyzes the value of ncRNAs as potential biomarkers to predict the outcome in PDAC and the possible mechanisms thereof.

Citations

Sep 24, 2015·Carcinogenesis·Chen-Yu Lin, Han-Mei Xu
May 22, 2016·Expert Review of Molecular Diagnostics·Ulrike Erb, Margot Zöller
Jan 3, 2018·Cancer Biology & Therapy·Yiran LiangQifeng Yang
Jul 29, 2016·World Journal of Gastroenterology : WJG·Sarah HeilerMargot Zöller
Sep 21, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yifan LianKeming Wang
Jun 8, 2017·Oncology Letters·Maria Celeste PalmarocchiPiercarlo Saletti
Nov 13, 2018·Journal of Cancer Research and Clinical Oncology·Tingting GuoPeng Gao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.